Literature DB >> 31097981

Focusing on Relevance: CETSA-Guided Medicinal Chemistry and Lead Generation.

Stina Lundgren1.   

Abstract

Confirmation of target engagement in relevant physiological environment ensures successful drug discovery and the right project prioritization. The Cellular Thermal Shift Assay (CETSA) offers a robust label-free method for studying protein-compound interactions in a cellular environment. This Viewpoint covers the broad applicability of CETSA in lead generation. The method can be used for deconvolution studies, target validation, screening of compound libraries, and hit confirmation. Moreover, the method is well suited for generation of relevant structure-activity relationship (SAR) data, enabling optimal compound design.

Year:  2019        PMID: 31097981      PMCID: PMC6511951          DOI: 10.1021/acsmedchemlett.9b00112

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  9 in total

1.  Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

Authors:  Daniel Martinez Molina; Rozbeh Jafari; Marina Ignatushchenko; Takahiro Seki; E Andreas Larsson; Chen Dan; Lekshmy Sreekumar; Yihai Cao; Pär Nordlund
Journal:  Science       Date:  2013-07-05       Impact factor: 47.728

2.  Trial watch: phase II and phase III attrition rates 2011-2012.

Authors:  John Arrowsmith; Philip Miller
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

3.  In Situ Target Engagement Studies in Adherent Cells.

Authors:  Hanna Axelsson; Helena Almqvist; Magdalena Otrocka; Michaela Vallin; Sara Lundqvist; Pia Hansson; Ulla Karlsson; Thomas Lundbäck; Brinton Seashore-Ludlow
Journal:  ACS Chem Biol       Date:  2018-02-21       Impact factor: 5.100

4.  Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay.

Authors:  Jerzy M Dziekan; Han Yu; Dan Chen; Lingyun Dai; Grennady Wirjanata; Andreas Larsson; Nayana Prabhu; Radoslaw M Sobota; Zbynek Bozdech; Pär Nordlund
Journal:  Sci Transl Med       Date:  2019-01-02       Impact factor: 17.956

5.  CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.

Authors:  Helena Almqvist; Hanna Axelsson; Rozbeh Jafari; Chen Dan; André Mateus; Martin Haraldsson; Andreas Larsson; Daniel Martinez Molina; Per Artursson; Thomas Lundbäck; Pär Nordlund
Journal:  Nat Commun       Date:  2016-03-24       Impact factor: 14.919

6.  Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay.

Authors:  Joseph Shaw; Mathew Leveridge; Charlotta Norling; Jakob Karén; Daniel Martinez Molina; Daniel O'Neill; James E Dowling; Paul Davey; Suzanna Cowan; Michael Dabrowski; Martin Main; Davide Gianni
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

7.  Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality.

Authors:  Mayumi Kitagawa; Pei-Ju Liao; Kyung Hee Lee; Jasmine Wong; See Cheng Shang; Noriaki Minami; Oltea Sampetrean; Hideyuki Saya; Dai Lingyun; Nayana Prabhu; Go Ka Diam; Radoslaw Sobota; Andreas Larsson; Pär Nordlund; Frank McCormick; Sujoy Ghosh; David M Epstein; Brian W Dymock; Sang Hyun Lee
Journal:  Nat Commun       Date:  2017-12-19       Impact factor: 14.919

8.  Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1.

Authors:  Joseph Shaw; Ian Dale; Paul Hemsley; Lindsey Leach; Nancy Dekki; Jonathan P Orme; Verity Talbot; Ana J Narvaez; Michal Bista; Daniel Martinez Molina; Michael Dabrowski; Martin J Main; Davide Gianni
Journal:  SLAS Discov       Date:  2018-12-13       Impact factor: 3.341

9.  CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.

Authors:  Tsuyoshi Ishii; Takuro Okai; Misa Iwatani-Yoshihara; Manabu Mochizuki; Satoko Unno; Masako Kuno; Masato Yoshikawa; Sachio Shibata; Masanori Nakakariya; Takatoshi Yogo; Tomohiro Kawamoto
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  9 in total
  2 in total

1.  A Novel Strategy for Regulating mRNA's Degradation via Interfering the AUF1's Binding to mRNA.

Authors:  Kun-Tao Li; Xiong-Zhi Wu; Zhi-Yin Sun; Tian-Miao Ou
Journal:  Molecules       Date:  2022-05-16       Impact factor: 4.927

2.  Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.

Authors:  Xin Li; Lajos Gera; Shumin Zhang; Yanhua Chen; Lei Lou; Lauren Marie Wilson; Zhong-Ru Xie; Giuseppe Sautto; Degang Liu; Alira Danaher; Kenza Mamouni; Yang Yang; Yuhong Du; Haian Fu; Omer Kucuk; Adeboye O Osunkoya; Jia Zhou; Daqing Wu
Journal:  Theranostics       Date:  2021-05-08       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.